The impact of oral contraceptives on cardiometabolic parameters

被引:12
作者
Farahmand, M. [1 ]
Tehrani, F. Ramezani [1 ]
Dovom, M. Rostami [1 ]
Hashemi, S. [1 ]
Azizi, F. [2 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Reprod Endocrinol Res Ctr, 24 Parvaneh St,Yaman St,POB 19395-4763, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, Tehran, Iran
关键词
Lipoproteins; Cardiovascular risk factors; Metabolic syndrome; Hypertension; Contraceptive pills; Tehran lipid and glucose study (TLGS); METABOLIC SYNDROME; LIPOPROTEIN METABOLISM; POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; CARDIOVASCULAR RISK; NATIONAL-HEALTH; A-I; PLASMA; LEVONORGESTREL; DESOGESTREL;
D O I
10.1007/s40618-015-0346-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose There is much controversy regarding the use of oral contraceptive pills (OCPs) on cardiometabolic parameters, which is why this longitudinal population-based study was conducted to assess the impact of OCP use and its duration on cardiometabolic factors. Methods Of 5532 reproductive-aged participants of the Tehran lipid and glucose study, 3160 women who met our inclusion criteria were subdivided according to the duration of OCPs consumption into four sub-groups: (1) Non-users; (2) <11 month users; (3) 12-35 month users, and (4) >= 36 month users, and their cardiometabolic parameters were compared. Results No statistical significant differences were observed between the cardiometabolic parameters of these sub-groups, after further adjustment for confounding factors including age, parity, and education, except for mean low-density lipoprotein-cholesterol which was significantly higher in women who used OCPs for >36 months in comparison to non-OCP users. The odds ratio of hypercholesterolemia was significantly higher in women who used OCPs for >36 months in comparison to non-OCP users; being 1.5 times higher than non-users (95 % CI 1.01-2.2). Conclusion Results showed that if used for less than 3 years, OCPs have no cardiometabolic effects.
引用
收藏
页码:277 / 283
页数:7
相关论文
共 36 条
[1]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[2]   Cardiovascular risk factors in an Iranian urban population: Tehran Lipid and Glucose Study (Phase 1) [J].
Azizi, F ;
Rahmani, M ;
Emami, H ;
Mirmiran, P ;
Hajipour, R ;
Madjid, M ;
Ghanbili, J ;
Ghanbarian, A ;
Mehrabi, Y ;
Saadat, N ;
Salehi, R ;
Mortazavi, N ;
Heydarian, P ;
Sarbazi, N ;
Allahverdian, S ;
Saadati, N ;
Ainy, E ;
Moeini, S .
SOZIAL-UND PRAVENTIVMEDIZIN, 2002, 47 (06) :408-426
[3]  
BLUM M, 1988, Advances in Contraception, V4, P143, DOI 10.1007/BF01849516
[4]   Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate [J].
Brinton, EA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (03) :431-440
[5]   EFFECTS OF ORAL CONTRACEPTIVE THERAPY ON RENIN-ANGIOTENSIN SYSTEM [J].
CAIN, MD ;
WALTERS, WA ;
CATT, KJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1971, 33 (04) :671-+
[6]   DIFFERENTIAL-EFFECTS OF ESTROGEN ON LOW-DENSITY-LIPOPROTEIN SUBCLASSES IN HEALTHY POSTMENOPAUSAL WOMEN [J].
CAMPOS, H ;
SACKS, FM ;
WALSH, BW ;
SCHIFF, I ;
OHANESIAN, MA ;
KRAUSS, RM .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (09) :1153-1158
[7]   Uniqueness of oral contraceptive progestins [J].
Carr, BR .
CONTRACEPTION, 1998, 58 (03) :23S-27S
[8]   Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles [J].
Cheung, MC ;
Walden, CE ;
Knopp, RH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (05) :658-664
[9]   Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials [J].
Coney, P ;
Washenik, K ;
Langley, RGB ;
DiGiovanna, JJ ;
Harrison, DD .
CONTRACEPTION, 2001, 63 (06) :297-302
[10]   Hormones and cardiovascular health in women [J].
Farley, T. ;
Fauser, B. ;
Glasier, A. ;
Greer, I. ;
Hanson, M. A. ;
La Vecchia, C. ;
Mishell, D. ;
Rosano, G. ;
Simon, T. ;
Baird, D. T. ;
Benagiano, G. ;
Collins, J. ;
Crosignani, P. G. ;
Diczfalusy, E. ;
Lanzone, A. ;
Negri, E. ;
Schmidt-Gollwitzer, K. ;
Skouby, S. O. ;
Volpe, A. .
HUMAN REPRODUCTION UPDATE, 2006, 12 (05) :483-497